Latest News
Gilead Sciences, Inc.
- Gilead to buy PepStar's inflammation drug program in $1.28 billion deal
- Gilead Sciences stock may move 4.6% on Oct. 29 earnings release
- Gilead's pill succeeds in mid-stage bowel disease trial
- Gilead ‘sitting on a foundational asset’ after oral UC drug's phase 2 win
- Gilead Sciences to present at three major healthcare conferences in September
- Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
- Form 144 GILEAD SCIENCES For: 16 October By Investing.com
- Vir, Gilead Partner on Novel T-Cell Engager Discovery
- Gilead Sciences signs five-year DevOps agreement with Cognizant
- Cognizant extends Gilead Sciences partnership for five years to expand AI-enabled DevOps
- Gilead partners with Calm to roll out disease-specific emotional wellness support
- Gilead Helps Patients Navigate the Emotional Journey of Diagnosis
Headlines from the last 30 days, linking to the original publishers. See all market news →